Supporting the local manufacture of diagnostics

Our team of expert process development and technical transfer scientists bridge the gap between innovation and impact. We work with partners in low- and middle-income country settings to build local R&D and lateral flow assay manufacturing capacity. We can provide full support with our quality and regulatory expertise and clinical trials team.

Global Access Diagnostics is committed to ensuring our innovations and tools get to those who need them most. This commitment is underpinned by our status as a social enterprise, which allows us to provide access to life-saving tools. We always prioritise impact and access above profit.

CASE STUDIES & NEWS ARTICLES

By GADx Team

Norbrook launches groundbreaking diagnostic test for Liver Fluke

Norbrook, a leader in animal health for over 50 years, is proud to announce the launch of a groundbreaking diagnostic test for liver fluke. Norbrook in cooperation with The…
Read more
By Dr Kevin Land

GHLabs x GADx: PoC innovation in molecular diagnostics

The sensitivity of molecular testing is now being revolutionised for point-of-care (PoC) usage. PCR, known for its high sensitivity and specificity, is the gold standard in diagnosing many infectious…
Read more
Packets of the IT-Leish rapid diagnostic test (RDT) for visceral leishmaniasis are displayed against a gradient background transitioning from teal to purple. Each white packet is clearly labeled with identification details including "IT LEISH", lot numbers, and expiration dates, along with the IVD (in vitro diagnostic) symbol, emphasizing their use in medical diagnostics. The packets are partially overlapped, focusing on their essential information and sterile packaging.
By Dr Sophie Owen

GADx reintroduces IT LEISH, the rapid diagnostic test for visceral leishmaniasis

Global Access Diagnostics (GADx), a social enterprise prioritising equitable access to diagnostics, today announced the launch of IT LEISH, a rapid diagnostic test (RDT) for visceral leishmaniasis (VL). The…
Read more
COVI-GO-1920w
By GADx Team

COVID-19 Rapid Antigen Self-Test, COVI-Go™, receives FDA Emergency Use Authorization for home use

Mologic Inc., the US subsidiary of  Global Access Diagnostics (GADx), a leading developer of lateral flow and rapid diagnostic technologies, products and services, announced today that its proprietary COVI-Go™…
Read more
Packets of the IT-Leish rapid diagnostic test (RDT) for visceral leishmaniasis are displayed against a gradient background transitioning from teal to purple. Each white packet is clearly labeled with identification details including "IT LEISH", lot numbers, and expiration dates, along with the IVD (in vitro diagnostic) symbol, emphasizing their use in medical diagnostics. The packets are partially overlapped, focusing on their essential information and sterile packaging.
By Dr Sophie Owen

GADx acquires manufacturing rights for IT LEISH rapid diagnostic test from Bio-Rad Laboratories

Global Access Diagnostics (GADx), a social enterprise prioritising equitable access to diagnostics and driving local manufacturing, today announced it has acquired the manufacturing rights for the IT LEISH rapid…
Read more

GET IN TOUCH

For sales inquiries please contact sales@globalaccessdx.com
For technical support please contact technicalsupport@globalaccessdx.com

Frequent testing is invaluable and so it is vital to find ways to drive down the cost of kits and increase production levels. As a social enterprise, GADx can transform this process because it ‘breaks the link’ of ‘having to make profit for shareholders’.

Paul Davis
Co-founder of Mologic and pioneer of lateral flow diagnostics.